Effect of Smoking Cessation on Mean Platelet Volume

Size: px
Start display at page:

Download "Effect of Smoking Cessation on Mean Platelet Volume"

Transcription

1 Original Article Effect of Smoking Cessation on Mean Platelet Volume Clinical and Applied Thrombosis/Hemostasis 19(3) ª The Author(s) 2013 Reprints and permission: sagepub.com/journalspermissions.nav DOI: / cath.sagepub.com Ercan Varol, MD 1, Atilla Icli, MD 1, Sule Kocyigit, MD 1, Dogan Erdogan, MD 1, Mehmet Ozaydin, MD 1, and Abdullah Dogan, MD 1 Abstract The aim of this study was to assess the values of mean platelet volume (MPV) in regular smokers and the effect of smoking cessation on MPV. The study group consisted of 116 regular smokers (57 females and 59 males; mean age years) and the control group was composed of 90 healthy volunteers (49 females and 41 males; mean age years). Platelet indices were assessed in regular smokers and control participants. Platelet indices were measured at 3 months after smoking cessation in these 101 participants. The MPV values were significantly higher in smokers than those of controls ( vs fl, respectively; P <.001). The MPV values decreased significantly at 3 months when compared with the baseline values ( vs fl, respectively; P <.001). We have found that serum MPV values were significantly higher in regular smokers than in controls. Serum MPV values decreased significantly at 3 months after smoking cessation. Keywords mean platelet volume, smoking, smoking cessation Introduction Chronic smoking is a major modifiable risk factor for the cardiovascular diseases. 1 it not only accelerates atherosclerosis but also causes endothelial dysfunction and hemostatic disorders. 2,3 Previous studies have demonstrated that chronic smoking cause platelet activation. 3-9 Mean platelet volume (MPV) is a potential marker of platelet reactivity. 10,11 In comparison to smaller ones, larger platelets have more granules, aggregate more rapidly with collagen, have higher thromboxane A2 level, and express more glycoprotein Ib and IIb/IIIa receptors Some studies have reported that smoking has no effect on MPV. 6,15 On the other hand, Kario et al have found increased MPV values in smokers. 16 Both the adverse effects of cigarette smoking and the benefits of smoking cessation on cardiovascular health occur rapidly. The risk of myocardial infarction falls by half within a year of cessation. 17 Although the risk of coronary artery disease after smoking cessation drops by approximately 50% one year after cessation, it approaches that of a person who has never smoked within 3 to 4 years. 18 It has been shown that smoking cessation improves platelet function. 2,19 To the best of our knowledge, there is no data about the effect of smoking cessation on MPV in smokers as a separate study. In this study, we aimed to assess MPV values in regular smokers and the effect of smoking cessation on MPV values. Patients and Methods The study group consisted of 116 regular smokers (57 females and 59 males; mean age years). Smokers were selected from persons who admitted to smoking cessation outpatient clinic. An age-, gender- and body mass index matched control group was composed of 90 healthy volunteers (49 females and 41 males; mean age years). In the present study, participants who smoke at least 8 cigarettes per day at least 3 years were considered as smokers. Nonsmokers (control group) were defined as those who had never smoked and were not exposed to environmental tobacco smoke. Biochemical measurements and platelet indices were assessed in116 regular smokers and 90 control participants. From 116 regular smokers, 101 participants successfully discontinued smoking. Platelet indices including MPV, platelet count and platelet distribution width (PDW), and white blood cell (WBC) count were 1 Department of Cardiology, Suleyman Demirel University, Faculty of Medicine, Isparta, Turkey Corresponding Author: Ercan Varol, Department of Cardiology, Suleyman Demirel Univesitesi Tıp Fakultesi, Sevket Demirel Kalp Merkezi, Isparta, Turkey. drercanvarol@yahoo.com

2 316 Clinical and Applied Thrombosis/Hemostasis 19(3) Table 1. Comparison of the Clinical and Laboratory Characteristics of the Smokers and. Smokers (n ¼ 116) (n ¼ 90) P Value a Age (years) Sex (M/F) 59/57 41/49.45 BMI (kg/m 2 ) SBP (mm Hg) DBP (mm Hg) Cigarettes/d (n) (8-40) Smoking period (years) (3-35) Glucose (mg/dl) Creatinine (mg/dl) Total cholesterol (mg/ dl) Triglycerides (mg/dl) LDL-cholesterol (mg/dl) HDL-cholesterol (mg/ dl) WBC (10 9 /L) Hemoglobin (g/dl) Platelet count (10 9 /L) <.001 MPV (fl) <.001 PDW Statin treatment n (%) 9 (7%) 0 (0%).005 cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol; WBC, white blood cell; MPV, mean platelet volume; PDW, platelet distribution width. measured at 3 months after smoking cessation in these 101 participants, and these values were compared with baseline platelet indices values of these 101 participants. Blood samples were drawn, at least 120 minutes after the last cigarette at admission to avoid the acute effects of smoking on platelet function. Hypertension was considered to be present if the systolic pressure was >140 mm Hg and/or diastolic pressure was >90 mm Hg or if the individual was taking antihypertensive medications. Diabetes mellitus was defined as a fasting blood glucose level >126 mg/dl or current use of a diet or medication to lower blood glucose. Exclusion criteria were history of heart disease, hypertension, diabetes mellitus, obesity, history of renal or liver disease, malignancy, current use of anticoagulant or antiplatelet drugs, or psychiatric disorders. The study was approved by the institutional ethics committee, and all patients gave their informed consent. Blood Sampling Blood sampling was performed at admission and at 3 months after smoking cessation. Blood samples were drawn from the antecubital vein by careful venipuncture in a 21 G sterile syringe without stasis between and AM after a fasting period of 12 hours. Glucose, creatinine, and lipid profiles were determined by standard methods. The MPV was measured in a blood sample collected in dipotassium EDTA tubes (Vacuette). An automatic blood counter (Beckman-Coulter Co, Miami, Florida) was used for whole blood counts. The MPV was recorded within 30 minutes prevent EDTAinduced swelling. Statistical Analysis Data were analyzed with the SPSS software version 10.0 for Windows. Continuous variables from the study groups were reported as mean + standard deviation and categorical variables as percentages. To compare continuous variables, the Student t test or Mann-Whitney U test was used where appropriate. Categorical variables were compared with the chisquare test. Paired samples t test was used to compare platelet indices between before and after smoking cessation. The correlations between MPV and other clinical and laboratory parameters were performed with Pearson correlation analysis. Statistical significance was defined as P <.05. Results Clinical and laboratory findings of the study and control groups were summarized in Table 1. There were no statistically significant differences between the 2 groups with respect to age, gender, body mass index, systolic and diastolic blood pressures, and levels of glucose, creatinine, total cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, hemoglobin, and PDW. The average number of cigarettes smoked per day was (8-40 cigarettes/d) for smokers. Average smoking period was years (3-35 years). The MPV values were significantly higher in smokers than those of controls ( vs fl, respectively; P <.001). Platelet count was significantly lower in smokers than that of controls ( vs /L [normal range: /L], respectively; P <.001). The WBC count was significantly higher in smokers than that of controls ( vs /L, respectively; P ¼.02). The correlation analysis in 116 smokers indicated that MPV was positively correlated with age (P <.001, r ¼.42), cigarettes smoked per day (P <.001, r ¼.81), smoking period (P <.001, r ¼.68), and negatively correlated with platelet count (P <.001, r ¼.35). We also compared the smokers and the control groups separately according to the gender. Clinical and laboratory findings of the study and control groups in male and female gender are summarized in Tables 2 3. The MPV values were significantly higher in smokers than those of controls ( vs fl, respectively; P <.001) and the platelet count was significantly lower in smokers than that of controls ( vs /L, respectively; P <.001) of male gender. The MPV values were significantly higher in smokers than those of controls ( vs fl respectively; P < 0.001) and the platelet count was

3 Varol et al 317 Table 2. Comparison of the Clinical and Laboratory Characteristics of the Smokers and in Male Gender. Smokers (n ¼ 59) (n ¼ 41) P Value a Age (years) BMI (kg/m 2 ) SBP (mm Hg) DBP (mm Hg) Cigarettes/d (n) Smoking period (years) Glucose (mg/dl) Creatinine (mg/dl) Total cholesterol (mg/dl) Triglycerides (mg/dl) LDL-cholesterol (mg/dl) HDL-cholesterol (mg/dl) WBC (10 9 /L) Hemoglobin (g/dl) Platelet count (10 9 /L) <.001 MPV (fl) <.001 PDW Statin treatment n (%) 6 (10%) 0 (0%).005 cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol; WBC, white blood cell; MPV, mean platelet volume; PDW, platelet distribution width. Table 3. Comparison of the Clinical and Laboratory Characteristics of the Smokers and in Female Gender. a Smokers (n ¼ 57) (n ¼ 49) P value Age (years) BMI (kg/m 2 ) SBP (mm Hg) DBP (mm Hg) Cigarettes/d (n) Smoking period (yrs) Glucose (mg/dl) Creatinine (mg/dl) Total cholesterol (mg/dl) Triglycerides (mg/dl) LDL-cholesterol (mg/dl) HDL-cholesterol (mg/dl) WBC (10 9 /L) Hemoglobin (g/dl) Platelet count (10 9 /L) <.001 MPV (fl) <.001 PDW Statin treatment n (%) 3 (5%) 0 (0%).005 cholesterol; HDL-cholesterol, high-density lipoprotein cholesterol; WBC, white blood cell; MPV, mean platelet volume; PDW, platelet distribution width. significantly lower in smokers than that of controls ( vs /L, respectively; P <.001) of female gender. The values of platelet indices before and after 3 months of smoking cessation in participants who succeeded to quit smoking are given in Table 4. The MPV decreased significantly at 3 months when compared with the baseline values ( vs fl, respectively; P <.001). Platelet count increased significantly at 3 month when compared with the baseline values ( vs /L, respectively; P <.001). However, WBC and PDW values did not change at 3 months of smoking cessation. Discussion In this study, we have found that MPV values were significantly higher in regular smokers than those of controls. The MPV was positively correlated with age, cigarettes smoked per day, and smoking period and negatively correlated with platelet count. The MPV values decreased significantly at 3 months after smoking cessation. The previous reports have shown that chronic smoking causes platelet activation. 3-9 It has also been shown that smoking cessation improves platelet function. 2,19 The MPV is a simple and easy method of assessing platelet function; and to the best of our knowledge, there is 1 data as a separate study, about the effect of smoking cessation on MPV values in smokers. Kario et al studied the effects of cigarette smoking and Table 4. Platelet Indices Before and After 3 Months of Smoking Cessation. Baseline (n ¼ 101) 3 months (n ¼ 101) P Value a WBC (10 9 /L) Platelet count (10 9 /L) <.001 MPV (fl) <.001 PDW Abbreviations: WBC, white blood cell; PDW, platelet distribution width; MPV, mean platelet volume. a P value is for comparison between control and study population overall. atherosclerotic risk factors on MPV. 16 They found that MPV was increased in elderly patients with atherosclerotic risk factors. They also reported a statistically significant decrease in MPV values in 8 smoking participants in the atherosclerotic group who successfully discontinued smoking. They suggested that smoking may increase platelet consumption in atherosclerotic vessels and that subsequently megakaryocytes are activated to produce more active larger platelets. Butkiewicz et al studied the effect of smoking on thrombocytopoiesis, platelet activation, and some morphological parameters including MPV in 60 healthy women (mean age years) and 65 healthy men (mean age years). 6 They found that, in neither of the sexes smoking had an effect on MPV. Recently, Arslan et al investigated the effects of smoking on MPV in young healthy male population (smokers 56 and nonsmokers 46, medium age: 22). 15 They found no significant

4 318 Clinical and Applied Thrombosis/Hemostasis 19(3) difference in MPV between the smoking and nonsmoking young aged healthy male participants. Our sample volume was greater than previous studies, and our study participants were composed of middle-aged participants. As a difference from previous studies, 6,15 we have found increased MPV in regular smokers in middle-aged participants. Our results confirm the results of the study performed by Kario et al in which the MPV was assessed in elderly patients with atherosclerotic risk factors. In these studies, only Kario et al reported the effect of smoking cessation on MPV in only 8 participants who successfully discontinued smoking. They reported a statistically significant decrease in MPV values after smoking cessation in 8 smoking participants. We also found a significant decrease in MPV values after 3 months of smoking cessation in 101 participants who successfully discontinued smoking. Our results also confirm the results of the study performed by Kario et al from this aspect. Smoking cessation is associated with a reduction in the risk of cardiovascular disease. 18 The risk of myocardial infarction falls by half within a year of cessation. Smoking cessation improves platelet function and this obviously has an important role in reduction of the cardiac events. 2,19 There are really few studies on the effect of smoking cessation on platelet function. Activated platelets release a wide variety of substances, 2 of which, platelet factor 4 and b-thromboglobulin, are commonly used as markers of platelet activation in vivo. Caponnetto et al studied changes in blood levels of surrogate markers of endothelial cell activation/injury (von Willebrand factor [vwf] and soluble thrombomodulin), clotting activation (D-Dimer and prothrombin fragments 1 þ 2), and platelet activation (platelet factor 4 and b-thromboglobulin) in regular smokers who participated in an intensive smoking cessation program. 2 They reported that significant reductions were observed on vwf activity as early as 2 months and significant reductions were observed on D-Dimer and prothrombin fragments F1 þ 2, platelet factor 4, and b-thromboglobulin concentrations at 6 and 12 months after smoking cessation. Caponnetto et al also showed a significant correlation between platelet activation markers; platelet factor 4 and b-thromboglobulin concentrations, and the number of packs per year in regular smokers. We also found that MPV was positively correlated with cigarettes smoked per day, smoking period consistent with this study. Activation of vascular endothelial cells is closely associated with platelet activation. As a result, they suggested that the reversal of endothelial function by smoking cessation may also improve platelet function indirectly. Morita et al investigated whether and how soon smoking cessation ameliorates impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability by improving the imbalance of the intraplatelet redox state. 19 It is well known that platelet aggregability is more augmented in chronic smokers than in nonsmokers. 4 They reported that only 2 weeks of smoking cessation can ameliorate the enhanced platelet aggregability and intraplatelet redox imbalance in long-term smokers, possibly by decreasing oxidative stress. In this study, we have also found that the regular smokers had lower platelet count than that of controls. The MPV has been shown to inversely correlate with the total platelet count, which could even suggest the consumption of small platelets and a compensatory production of larger reticulated platelets. 20 We do not know the exact cause of the decrease in MPV values after smoking cessation. Platelet activation is one of the major factors by which tobacco smoke mediates the pathogenesis of cardiovascular diseases, which may be related to endothelial dysfunction and/or direct effects of oxidant chemicals. 21 Smoking-related endothelial dysfunction results in reduced release of nitric oxide that normally inhibits platelet activation. 22 As a result, restoration of endothelial function and/or decrease in oxidative stress may possibly improve platelet function within months after smoking cessation. The present study has some study limitations. Smoking status was monitored from self-reports given by participants. Abstinence from smoking was not reviewed objectively by measuring the concentrations of carbon monoxide in expired breath. In conclusion, we have found that the MPV values were significantly higher in smokers than those of controls. The MPV was positively correlated with age, cigarettes smoked per day, and smoking period and negatively correlated with platelet count. The MPV values decreased significantly at 3 months after smoking cessation. Our results may contribute to the understanding of the pathophysiological link of smoking cessation to beneficial cardiovascular effects. Our results may strengthen the motivation for smokers to quit smoking. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. References 1. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis. 2009;205(1): Caponnetto P, Russo C, Di Maria A, et al. Circulating endothelialcoagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest. 2011;41(6): FitzGerald GA, Oates JA, Nowak J. Cigarette smoking and hemostatic function. Am Heart J. 1988;115(1 pt 2): Takajo Y, Ikeda H, Haramaki N, Murohara T, Imaizumi T. Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol. 2001;38(5): Lupia E, Bosco O, Goffi A, et al. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis. 2010;210(1):

5 Varol et al Butkiewicz AM, Kemona-Chetnik I, Dymicka-Piekarska V, Matowicka-Karna J, Kemona H, Radziwon P. Does smoking affect thrombocytopoiesis and platelet activation in women and men? Adv Med Sci. 2006;51: Rangemark C, Benthin G, Granstrom EF, Persson L, Winell S, Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation. 1992;86(5): Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation. 1987;76(1): Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995;92(9): Park Y, Schoene N, Haris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002;13(5-6): Boos CJ, Lip GY. Assessment of mean platelet volume in coronary artery disease-what does it mean? Thromb Res. 2007;120(1): Martin JF, Trowbridge EA, Salmon GL, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res. 1983;32(5): Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. Br J Haematol. 1983;53(3): Giles H, Smith REA, Martin JF. Platelet glycoprotein IIb IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest. 1994;24(1): Arslan E, Yakar T, Yavaşoğlu I. The effect of smoking on mean platelet volume and lipid profile in young male subjects. Anadolu Kardiyol Derg. 2008;8(6): Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992;14(4): Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997;96(4): U.S. Department Of Health And Human Services. The Health Benefits of Smoking Cessation: A Report Of The Surgeon General, DHHS Publication No. (CDC) Rockville, MD: U.S. Department Of Health And Human Services, Public Health Service, Centers For Disease Control And Prevention; Morita H, Ikeda H, Haramaki N, Eguchi H, Imaizumi T. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J Am Coll Cardiol. 2005;45(4): Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10): Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46(1): Ichiki K, Ikeda H, Haramaki N, Ueno T, Imaizumi T. Long-term smoking impairs platelet-derived nitric oxide release. Circulation. 1996;94(12):

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Comparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography

Comparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography Global Journal of Health Science; Vol. 8, No. 11; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Comparison of Mean Platelet Volume in Acute Myocardial Infarction

More information

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures

More information

Only Two-Week Smoking Cessation Improves Platelet Aggregability and Intraplatelet Redox Imbalance of Long-Term Smokers

Only Two-Week Smoking Cessation Improves Platelet Aggregability and Intraplatelet Redox Imbalance of Long-Term Smokers Journal of the American College of Cardiology Vol. 45, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.10.061

More information

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise

More information

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple

More information

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients

More information

Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform?

Preventing Myocardial Infarction in the Young Adult in the First Place: How Do the National Cholesterol Education Panel III Guidelines Perform? Journal of the American College of Cardiology Vol. 41, No. 9, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00187-6

More information

Reeju Manandhar, Chaofeng Sun. Original article

Reeju Manandhar, Chaofeng Sun. Original article Original article Association of different blood parameters with the early patency of Infarct related artery in ST elevation Myocardial Infarction, a comparative analysis. Reeju Manandhar, Chaofeng Sun

More information

The Impact of Smoking on Acute Ischemic Stroke

The Impact of Smoking on Acute Ischemic Stroke Smoking The Impact of Smoking on Acute Ischemic Stroke Wei-Chieh Weng, M.D. Department of Neurology, Chang-Gung Memorial Hospital, Kee-Lung, Taiwan Smoking related mortality Atherosclerotic vascular disease

More information

Guidelines on cardiovascular risk assessment and management

Guidelines on cardiovascular risk assessment and management European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine

More information

NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS EPTIFIBATIDE (INTEGRILIN) PROTOCOL

NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE PROTOCOLS EPTIFIBATIDE (INTEGRILIN) PROTOCOL NURSING DEPARTMENT CRITICAL CARE POLICY MANUAL CRITICAL CARE S EPTIFIBATIDE (INTEGRILIN) I. PURPOSE: A. Integrilin (Eptifibatide) is a specific and potent inhibitor of the platelet receptor glycoprotein

More information

Topic 1: Lifestyle, Health and Risk

Topic 1: Lifestyle, Health and Risk alevelbiology.co.uk Topic 1: Lifestyle, Health and Risk SPECIFICATION Many animals have a heart and circulation (mass transport to overcome limitations of diffusion in meeting the requirements of organisms).

More information

International Journal of Pharma and Bio Sciences PLATELET VOLUME INDICES (PVI) IN METABOLIC SYNDROME (MS) ABSTRACT

International Journal of Pharma and Bio Sciences PLATELET VOLUME INDICES (PVI) IN METABOLIC SYNDROME (MS) ABSTRACT Research Article Biochemistry International Journal of Pharma and Bio Sciences ISSN 0975-6299 PLATELET VOLUME INDICES (PVI) IN METABOLIC SYNDROME (MS) DR. DHARMIK S. PATEL *1, DR. KILLOL N. DESAI 2, DR.

More information

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL

More information

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

La Trombosi Arteriosa

La Trombosi Arteriosa La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They

More information

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh

Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh "Insight Heart" is also available at www.squarepharma.com.bd Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh Coronary heart disease has been emerging as an

More information

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and 1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial

More information

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:

More information

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)

More information

Cardiovascular Disease Risk Factors:

Cardiovascular Disease Risk Factors: Cardiovascular Disease Risk Factors: Risk factors are traits or habits that increase a person's chances of having cardiovascular disease. Some risk factors can be changed. These risk factors are high blood

More information

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±

More information

A study on platelet volume indices in acute coronary syndrome

A study on platelet volume indices in acute coronary syndrome Original Research Article A study on platelet volume indices in acute coronary syndrome G. Ranjani 1*, S. Manikandan 2, I. Rohini 3, S. Kalaiselvi 4 1,2,3,4 Assistant Professor, Department of Medicine,

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines

More information

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients

Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients ORIGINAL ARTICLES Epidemiologic and clinical comparison of renal artery stenosis in black patients and white patients Andrew C. Novick, MD, Safwat Zald, MD, David Goldfarb, MD, and Ernest E. Hodge, MD,

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

Welcome and Introduction

Welcome and Introduction Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for

More information

2013 Hypertension Measure Group Patient Visit Form

2013 Hypertension Measure Group Patient Visit Form Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part

More information

Supplementary Note Details of the patient populations studied Strengths and weakness of the study

Supplementary Note Details of the patient populations studied Strengths and weakness of the study Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined

More information

ASSeSSing the risk of fatal cardiovascular disease

ASSeSSing the risk of fatal cardiovascular disease ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

10/17/16. Assessing cardiovascular risk through use of inflammation testing

10/17/16. Assessing cardiovascular risk through use of inflammation testing Assessing cardiovascular risk through use of inflammation testing Anthony L. Lyssy, DO Medical Director and Managing Partner Diamond Physicians Dallas, TX Response to Injury Hypothesis Injury Response

More information

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016 Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October

More information

Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases

Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases Relationship between serum glutathione peroxidase-1activity with endothelial dysfunction level in patients with coronary artery diseases Introduction Reactive oxygen species (ROS),such as superoxide and

More information

Case Study: Chris Arden. Peripheral Arterial Disease

Case Study: Chris Arden. Peripheral Arterial Disease Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Long-Term Complications of Diabetes Mellitus Macrovascular Complication Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence

More information

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI) Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension

More information

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community International Journal of Scientific and Research Publications, Volume 4, Issue 4, April 214 1 The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community Mulugeta

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

Annals of RSCB Vol. XVI, Issue 1

Annals of RSCB Vol. XVI, Issue 1 THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

Chapter 18. Diet and Health

Chapter 18. Diet and Health Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in

More information

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

Association between arterial stiffness and cardiovascular risk factors in a pediatric population + Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2

Intercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2 Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter

More information

Diabetes Mellitus: A Cardiovascular Disease

Diabetes Mellitus: A Cardiovascular Disease Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular

More information

Study of relationship between Platelet Volume Indices and Hyperlipidemia

Study of relationship between Platelet Volume Indices and Hyperlipidemia Original Article Study of relationship between Platelet Volume Indices and Hyperlipidemia Rashi Khemka 1 *, Kalpana Kulkarni 2 1 Department of Pathology, Delhi State Cancer Institute, Delhi, India-110095

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

The Diabetes Link to Heart Disease

The Diabetes Link to Heart Disease The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal

Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Prediction of Cardiovascular Disease in suburban population of 3 municipalities in Nepal Koju R, Gurung R, Pant P, Humagain S, Yogol CM, Koju A, Manandhar K, Karmacharya B, Bedi TRS Address for Correspondence:

More information

year resident, Department of Medicine, B. J. Medical college, Ahmedabad.

year resident, Department of Medicine, B. J. Medical college, Ahmedabad. Clinical Study of Type 2 Diabetes Mellitus Patients with or without Cerebrovascular Feature and Its Correlation with Other Comorbidity / Diabetic Complication Vivek Sidhapura 1*, Bipin Amin 2, Amit Potulwar

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG.

ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Hyperglycemia and Coronary Events: where is the link? ATEF ELBAHRY,FACA,FICA,MISCP,FVBWG. Cardiovascular (CV) disease is the primary complication of diabetes ~65% of deaths are due to CV disease Coronary

More information

Cardiac Pathophysiology

Cardiac Pathophysiology Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of

More information

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease

Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,

More information

C-Reactive Protein and Your Heart

C-Reactive Protein and Your Heart C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory

More information

Permission Granted!! Women Take Care of Your Hearts! October 22, 2016

Permission Granted!! Women Take Care of Your Hearts! October 22, 2016 Associate Director of Clinical Trials Division of Cardiovascular Medicine University of Florida 1 1. Cancer 2. Housework 3. Heart Disease 4. Children who don t leave home 5. 2, 3, 4 10/25/2016 12:36 PM

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

Depok-Indonesia STEPS Survey 2003

Depok-Indonesia STEPS Survey 2003 The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural

More information

Section 03: Pre Exercise Evaluations and Risk Factor Assessment

Section 03: Pre Exercise Evaluations and Risk Factor Assessment Section 03: Pre Exercise Evaluations and Risk Factor Assessment ACSM Guidelines: Chapter 3 Pre Exercise Evaluations ACSM Manual: Chapter 3 Risk Factor Assessments HPHE 4450 Dr. Cheatham Purpose The extent

More information

Page down (pdf converstion error)

Page down (pdf converstion error) 1 of 6 2/10/2005 7:57 PM Weekly August6, 1999 / 48(30);649-656 2 of 6 2/10/2005 7:57 PM Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke -- United States, 1900-1999

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease

American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease American Medical Women s Association Position Paper on Principals of Women & Coronary Heart Disease AMWA is a leader in its dedication to educating all physicians and their patients about heart disease,

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor

More information

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke

More information

Heart Disease. Signs and Symptoms

Heart Disease. Signs and Symptoms Heart Disease The term "heart disease" refers to several types of heart conditions. The most common type is coronary artery disease, which can cause heart attack, angina, heart failure, and arrhythmias.

More information

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant

More information

Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different?

Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Eicosapentaenoic Acid and Docosahexaenoic Acid: Are They Different? Trevor A Mori, Ph.D., Professor, School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth,

More information

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI Narbeh Melikian*, Ajay M Shah*, Martyn R Thomas, Roy Sherwood, Mark T

More information

Diabete ed ASA: cosa c è di nuovo?

Diabete ed ASA: cosa c è di nuovo? Università Magna Græcia di Catanzaro Dipartimento di Medicina Sperimentale e Clinica Cattedra di Medicina Interna ed U.O. Malattie Cardiovascolari Scuola di Specializzazione in Geriatria Prof. Francesco

More information

Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity

Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity 71 P.P.Bidzilya Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

http://noodlemaz.wordpress.com/category/science/cancer/ Outline Introduction Serious nature of Cardiovascular Disease (CVD) How to prevent CVD? The disease process Damage and plaque development Current

More information

Cardiovascular System and Health. Chapter 15

Cardiovascular System and Health. Chapter 15 Cardiovascular System and Health Chapter 15 Cardiovascular Disease Leading cause of death in U.S. Claims 1 life every 43 seconds Often, the first sign is a fatal heart attack Death Rates #1 CVD #2 Cancer

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care

Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care

More information

Hyperuricemia as a Prognostic Marker in Acute Ischemic Stroke

Hyperuricemia as a Prognostic Marker in Acute Ischemic Stroke Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/23 Hyperuricemia as a Prognostic Marker in Acute Ischemic Stroke B Balaji 1, Bingi Srinivas 2 1 Associate Professor,

More information

The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction

The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.

More information